Partnerships for African Vaccine Manufacturing
7th Annual AGOA CSO Network Spring Conference

20 April 2022
The AU has set a goal to ensure 60% of the vaccines administered in Africa are locally manufactured and mandated the PAVM to oversee this task.

Context

The African Union calls for a New Public Health Order aimed at safeguarding the health and economic security of the continent.

The first pillar of the New Public Health Order is expanding manufacturing of vaccines, diagnostics and therapeutics.¹

Ambition to be enabled by the Framework for Action

The African Union has set a goal to increase vaccine manufacturing on the African continent to meet 60% of the demand by 2040 and mandated the Partnerships for African Vaccine Manufacturing (PAVM) to develop a Framework for Action to execute this.

¹ Other pillars include: Strengthened public health institutions, Strengthened public health workforce, Respectful, action-oriented partnerships.
The PAVM was established under the Africa CDC with four broad objectives to guide its operations.

PAVM’s four broad objectives:

- **Steward a continental strategy** that maintains scale and cost-competitiveness of local manufacturing and promotes equity and security for all.
- **Support partnerships** to create a conducive business environment that will encourage the emergence of a thriving manufacturing base.
- **Play intermediation and partner role** between Member States and the global community of supporters on an as-needed basis.
- **Communicate updates** and serve as the central source of information for Africa Vx manufacturing.
PAVM has made great strides in the past year and will need the support of partners to implement the bold programs outlined in the Framework for Action.

- Facilitated the African Vaccine Manufacturing Summit which mandated PAVM and set the target ambitions.
- The PAVM was approved by AU Executive Council.
- Hosted a successful Stakeholder Engagement Event in Kigali where significant decisions were made on the FFA bold programs.
- Operationalised the PAVM, setting up a task force of 7 workstreams consisting >60 members which hosted >30 hours of workshops and >100 hours of working sessions.
- Finalised Draft 1.0 of the FFA that was peer reviewed by independent experts and scientists.
- FFA has been endorsed at the Heads of State Assembly.
- Facilitated the African Vaccine Manufacturing Summit which mandated PAVM and set the target ambitions.
- 2021
  - May: Operationalised the PAVM, setting up a task force of 7 workstreams consisting >60 members which hosted >30 hours of workshops and >100 hours of working sessions.
  - November: Hosted a successful Stakeholder Engagement Event in Kigali where significant decisions were made on the FFA bold programs.
  - 17 December: Finalised Draft 1.0 of the FFA that was peer reviewed by independent experts and scientists.
  - 5/6 February: FFA has been endorsed at the Heads of State Assembly.
- 2022
  - 12-13 April: Facilitated the African Vaccine Manufacturing Summit which mandated PAVM and set the target ambitions.
  - May: Operationalised the PAVM, setting up a task force of 7 workstreams consisting >60 members which hosted >30 hours of workshops and >100 hours of working sessions.
  - 6-7 December: Hosted a successful Stakeholder Engagement Event in Kigali where significant decisions were made on the FFA bold programs.
  - 17 December: Finalised Draft 1.0 of the FFA that was peer reviewed by independent experts and scientists.
  - 5/6 February: FFA has been endorsed at the Heads of State Assembly.
  - Rest of 2022: Draft 2.0 of the FFA is ready for dissemination.
  - Working with partners to build PAVM structures and bolster the bold programs, with oversight from PAVM’s Project Management Office.
PAVM developed a continental strategy that outlines diseases, technology platforms and manufacturing value chain steps that Africa needs to prioritise.

**Potential disease prioritization**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Vaccine exists</th>
<th>Vaccine does not exist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yellow fever</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholera</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Potential value chain focus**

- **Fill & Finish (F&F)**: Fill & finish for all priority vaccines, enabling achievement of local production targets.
- **Innovative**
  - Live attenuated
  - Inactivated virus
  - Subunit
  - Virus-like particle
  - Viral vector
  - RNA/DNA
- **Expanding**
  - HPV
  - Pneumococcal
  - HIV
  - COVID-19
  - Malaria
  - Rotavirus
- **Outbreak**
  - Ebola
  - Chikungunya
  - Lassa fever
  - Rift valley fever
  - Disease X

**Technology focus**

... requiring a breadth of technology platforms...

- **Legacy**: Tetanus, Diphtheria, Yellow fever, Measles, Cholera, Meningococcal
- **Expanding**: HPV, Pneumococcal, HIV, COVID-19, Malaria, Rotavirus
- **Outbreak**: Ebola, Chikungunya, Lassa fever, Rift valley fever, Disease X

... along the different steps of the value chain

- **Live attenuated**
- **Inactivated virus**
- **Subunit**
- **Virus-like particle**
- **Viral vector**
- **RNA/DNA**

- **Drug Substance (DS)**: Expand drug substance mostly in established platforms.
- **R&D**: Expand R&D activities to develop new vaccines for Africa, support more efficient manufacturing and improve vaccine characteristics.
The Framework for Action defines 8 bold programs that will support the growing momentum of vaccine manufacturing in Africa.

1. African Vaccines Procurement Pooling Mechanism
2. Vaccine manufacturing deal preparation and financing facility
3. Embedding Vaccines regulatory excellence in NRAs and RCOREs through AMA and AMRH
4. Vaccine Technology Transfer & IP Enablement Unit
5. Regional Capability and Capacity centres
6. Vaccine R&D centres and R&D coordinating unit
7. Advocacy for enabling trade policies for Vaccines
8. Continental strategy delivery and oversight
PAVM will rely on several strategic partnerships to deliver on these 8 bold programs.
The PAVM will start working with partners to operationalise the bold programs and will work jointly with AU member states as they start scaling up manufacturing activities.

**Key action plan for PAVM in 2022**

- Continue running PAVM’s Project Management Office to provide oversight and support to vaccine manufacturing initiatives in Africa
- Continue engagements with frontrunner countries, RECs, manufacturers and other stakeholders to develop joint action plans to scale up manufacturing
- Work with partners to implement the bold programs
- Implement a broad communications strategy
- Refine the FFA based on inputs from stakeholder engagements